PAOLA-1 / ENGOT-ov25
Adding olaparib to bevacizumab maintenance roughly doubled progression-free time in tumours with faulty DNA repair, and improved survival in that group.
PFS 22.1 vs 16.6 months overall (HR 0.59) and 37.2 vs 17.7 months in HRD-positive tumours (HR 0.33; NEJM 2019). Five-year OS in HRD-positive patients was 65.5% vs 48.4% (HR 0.62; Annals of Oncology 2023). No benefit in HRD-negative disease. Approved in 2020 for HRD-positive tumours; it established HRD testing as a decision point.
- Median 37.2 vs 17.7 months with Olaparib + bevacizumab compared with Placebo + bevacizumab; about 19.5 months longer for half the group.
- A median is a midpoint: half the people did better than this and half did worse, so it is not a prediction for any one person.
- Put another way, the treated group had about 67 percent lower chance of the event at any given time (hazard ratio 0.33, likely range 0.25 to 0.45).
- This is a surrogate endpoint: it measures the cancer being controlled or absent on scans and tests, which often, but not always, translates into living longer.
- 65.5 vs 48.4 out of 100 alive at 5 years with Olaparib + bevacizumab compared with Placebo + bevacizumab; 17.1 more per 100.
- Roughly one extra person helped for every 6 treated. That is a rough figure taken from the two percentages, not a guarantee for any one person.
- Put another way, the treated group had about 38 percent lower chance of the event at any given time (hazard ratio 0.62, likely range 0.45 to 0.85).
- Overall survival counts deaths from any cause, so it is the most direct measure of whether a treatment helps people live longer.
- These results apply to the people the trial enrolled: Newly diagnosed advanced ovarian cancer already on bevacizumab maintenance: adding olaparib vs placebo. People in a different situation may not see the same effect.
Numbers are from the trial as recorded here; see the source links in the table below. This is orientation, not medical advice: ask your team how closely the trial population matches you.
Pages like this
not linked directly; found by shared links- IdeaA functional test for homologous recombination deficiency validated across laboratories
Shares Homologous recombination deficiency (HRD), Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- TechnologyHRD & BRCA testing
Shares ARCAGY-GINECO, Society of Gynecologic Oncology, Homologous recombination deficiency (HRD), PARP.
- TrialGOG-0218 & ICON7 (bevacizumab)
Shares ARCAGY-GINECO, Bevacizumab, VEGF / VEGFR, Ovarian cancer.
- TrialSOLO-1
Shares Olaparib, PARP, BRCA1 / BRCA2 (HRD), Ovarian cancer.
- TrialDUO-O / ENGOT-ov46
Shares Bevacizumab, Olaparib, PARP, Ovarian cancer.
- PersonUrsula A. Matulonis
Shares Society of Gynecologic Oncology, Olaparib, PARP, Ovarian cancer.
- PersonAlan Ashworth
Shares Olaparib, PARP, BRCA1 / BRCA2 (HRD), Ovarian cancer.
- TrialPROfound
Shares Olaparib, PARP, BRCA1 / BRCA2 (HRD).